Novartis poaches Bristol-Myers/Amgen vet John Tsai for top drug development post in a $9B organization
Novartis CEO Vas Narasimhan has found his replacement as head of their global drug development organization at Amgen, a big pharma partner which has led the work on their new migraine drug.
John Tsai, the chief medical officer at Amgen, is now taking the job Narasimhan left as he moved up to the top suite in Basel. And he’ll be taking one of the most visible jobs in drug R&D at a group that spends about $9 billion a year on everything from discovery to approval — in the top 3 R&D budgets on the planet with Merck and Roche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.